# OLE of Phase 2b/3 Study ANAVEX2-73-AD-004

> **NCT04314934** · PHASE2,PHASE3 · COMPLETED · sponsor: **Anavex Life Sciences Corp.** · enrollment: 300 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** ANAVEX2-73

## Key facts

- **NCT ID:** NCT04314934
- **Lead sponsor:** Anavex Life Sciences Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-10
- **Primary completion:** 2024-06-14
- **Final completion:** 2024-06-14
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2024-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04314934

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04314934, "OLE of Phase 2b/3 Study ANAVEX2-73-AD-004". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04314934. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*